CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

Overview of attention for article published in Multiple Sclerosis and Related Disorders, January 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 5 posts from 1 blogs.

I think we have had enough of COVID-19 and there is not much new to say, but when the publications are relevant to our work…

Someone said that my last long-post was not an “Easy read”. I suggested that in the Post-G era, I could’nt be bothered with…

It is early days but omicron is spreading fast, but the good news perhaps is that infected people are doingrelatively OK so far…

Give all your nursing/neurology and MS friends an early Christmas…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity, including 1 additional blog posts.